Today, unmet needs are driving global demand for safer, more robust and efficacious infectious disease drugs. Unfortunately, many factors challenge the discovery of global solutions — factors like global mobility, the rapid emergence of antibiotic resistance and the rise of hospital acquired infections. Our successful experience in developing infectious disease solutions leverage unique thinking and capabilities that span preclinical and clinical capabilities across the areas of bacterial, viral, fungal and parasitic diseases. In fact, we’ve worked on more than 150 infectious disease studies — including three of the last four antibiotics approved — and leverage this expertise to shape new opportunities for you.
Hepatitis C is a significant medical challenge that we’re actively partnering to cure. With research rapidly advancing and new treatment paradigms the competitive landscape of new drugs in development requires rapid testing to provide both medical and economic proof of efficacy. In addition, we have successfully brought multiple influenza and HIV solutions to market. From genomics to clinical development to safety and viral testing in our central laboratories, we are relentless in our promise to provide you guidance and help deliver solutions made real.